Authors: Margolin, K Gordon, MS Holmgren, E Gaudreault, J Novotny, W Fyfe, G Adelman, D Stalter, S Breed, J

Citation: K. Margolin et al., Phase Ib trial of intravenous recombinant humanized monoclonal antibody tovascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data, J CL ONCOL, 19(3), 2001, pp. 851-856

Authors: Fisher, RI Rosenberg, SA Fyfe, G

Citation: Ri. Fisher et al., Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, CA J SCI AM, 6, 2000, pp. S55-S57

Authors: Davey, RT Chaitt, DG Albert, JM Piscitelli, SC Kovacs, JA Walker, RE Falloon, J Polis, MA Metcalf, JA Masur, H Dewar, R Baseler, M Fyfe, G Giedlin, MA Lane, HC

Citation: Rt. Davey et al., A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection, J INFEC DIS, 179(4), 1999, pp. 849-858

Authors: Somlo, G Sniecinski, I ter Veer, A Longmate, J Knutson, G Vuk-Pavlovic, S Bhatia, R Chow, W Leong, L Morgan, R Margolin, K Raschko, J Shibata, S Tetef, M Yen, Y Forman, S Jones, D Ashby, M Fyfe, G Hellmann, S Doroshow, JH

Citation: G. Somlo et al., Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy, BLOOD, 93(9), 1999, pp. 2798-2806